Enanta Pharmaceuticals, Inc. (ENTA) has a negative trailing P/E of -4.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -24.27%.
Criteria proven by this page:
Overall SharesGrow Score: 44/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | 23.2 | -0.32 | 1.87 | 5.71 | - |
| 2017 | 50.4 | -2.74 | 2.96 | 8.68 | - |
| 2018 | 24.1 | 0.09 | 4.41 | 8.41 | - |
| 2019 | 25.4 | -0.80 | 2.54 | 5.73 | - |
| 2020 | -25.2 | 0.14 | 2.00 | 7.45 | - |
| 2021 | -14.5 | -0.12 | 2.87 | 11.80 | - |
| 2022 | -8.8 | -0.17 | 3.33 | 12.40 | - |
| 2023 | -1.8 | -0.22 | 1.08 | 2.96 | - |
| 2024 | -1.9 | 0.13 | 1.70 | 3.24 | - |
| 2025 | -3.1 | 0.10 | 3.95 | 3.91 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $1.13 | $88.27M | $21.67M | 24.5% |
| 2017 | $0.91 | $102.81M | $17.71M | 17.2% |
| 2018 | $3.48 | $206.63M | $71.96M | 34.8% |
| 2019 | $2.21 | $205.2M | $46.38M | 22.6% |
| 2020 | $-1.81 | $122.47M | $-36.17M | -29.5% |
| 2021 | $-3.92 | $97.07M | $-79M | -81.4% |
| 2022 | $-5.91 | $86.16M | $-121.76M | -141.3% |
| 2023 | $-6.38 | $79.2M | $-133.82M | -169% |
| 2024 | $-5.48 | $67.64M | $-116.05M | -171.6% |
| 2025 | $-3.84 | $65.32M | $-81.89M | -125.4% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-2.47 | $-3.07 – $-1.63 | $66.49M | $64.46M – $69.3M | 3 |
| 2027 | $-1.99 | $-2.54 – $-1.61 | $63.09M | $57.84M – $70.6M | 4 |
| 2028 | $-2.18 | $-3.88 – $-1.31 | $64.65M | $58.35M – $71.55M | 3 |
| 2029 | $-1.63 | $-1.85 – $-1.42 | $67.95M | $61.33M – $75.21M | 1 |
| 2030 | $-2.19 | $-2.49 – $-1.91 | $57.1M | $51.54M – $63.2M | 1 |
